Related Experiment Video
Updated: Jul 9, 2026
Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain
Published on: October 25, 2016
Generation of Her-2/neu vaccine utilizing idiotypic network cascade
Smarajit Pal1, Asim Saha, Kartik Mohanty
1Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA.
Abstract:
Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or overexpression of Her-2/neu occur in multiple human malignancies and are associated with poor prognosis. The Her-2/neu proto-oncogene is a suitable target for cancer immunotherapy. Our strategy is active specific immunotherapy in which patients immunized with an anti- Id antibody mimicking Her-2/neu will generate sustained high titer Her-2/neu specific protective antibodies. We have used an anti-Her-2/neu murine monoclonal antibody 4D5 as the immunizing antibody (Ab1) against which monoclonal anti-Ids or Ab2s were generated in syngeneic mice. We have characterized one such anti-Id (Ab2) designated 6D12, which mimics a specific epitope of Her-2/neu as defined by Trastuzumab, and can be used as a surrogate antigen for Her-2/neu across the species barriers. Immunization of allogeneic mice or rabbits with 6D12 induced anti-anti-Id (Ab3), that specifically recognized Her-2/neu-positive tumor cells and lysed these cells in culture by antibody-dependent cellular cytotoxicity (ADCC). Monoclonal Ab3 generated in mice against 6D12 inhibited the proliferation of Her-2/neu-positive SK-BR-3 cells in vitro in a dose dependent fashion and delayed the growth of Her-2/neu transfected EL4-Her-2 cells in vivo. These data suggest the potential use of 6D12 as a vaccine for Her-2/neu-positive human cancer.
Insights
An anti-idiotype antibody vaccine approach targets Her-2/neu-positive cancers. This novel immunotherapy strategy, using the 6D12 antibody, successfully generated protective antibodies and demonstrated tumor cell lysis and growth inhibition in preclinical models.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Her-2/neu proto-oncogene amplification/overexpression is linked to poor prognosis in various human cancers.
- Her-2/neu is a validated target for cancer immunotherapy.
- Current therapeutic strategies require novel approaches for effective treatment.
Purpose of the Study:
- To investigate an anti-idiotype (Id) antibody-based vaccine for treating Her-2/neu-positive human cancers.
- To develop a vaccine that elicits sustained, high-titer Her-2/neu-specific protective antibodies through active specific immunotherapy.
- To evaluate the efficacy of a specific anti-Id antibody, 6D12, as a potential cancer vaccine.
Main Methods:
- Generated monoclonal anti-Id antibodies (Ab2) using an anti-Her-2/neu antibody (4D5) as the immunogen (Ab1).
- Characterized anti-Id antibody 6D12 for its ability to mimic a Her-2/neu epitope recognized by Trastuzumab.
- Induced anti-anti-Id antibodies (Ab3) in allogeneic animals immunized with 6D12 and assessed their anti-tumor activity in vitro and in vivo.
Main Results:
- The anti-Id antibody 6D12 effectively mimics a key Her-2/neu epitope, serving as a surrogate antigen.
- Immunization with 6D12 generated Ab3 antibodies that specifically recognized and lysed Her-2/neu-positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).
- Monoclonal Ab3 antibodies inhibited proliferation of SK-BR-3 cells in vitro and delayed tumor growth of EL4-Her-2 cells in vivo.
Conclusions:
- The anti-idiotype antibody 6D12 shows promise as a vaccine candidate for Her-2/neu-positive cancers.
- This approach demonstrates the potential for generating specific anti-tumor immune responses using anti-Id antibodies.
- Further development of this vaccine strategy could offer a new therapeutic option for patients with Her-2/neu-driven malignancies.
